Table 3.
Prognostic value of mregDCs in cancer.
| Cancer | Method | Samples | Species | Markers | Findings | Name | Ref. |
|---|---|---|---|---|---|---|---|
| ESCC | IHC | 80 surgical treated without pre-opt care | Human | LAMP-3 | Infiltrating LAMP-3+ DCs correlated with intratumoral CD8+ T cells, which correlated with a favorable prognosis | LAMP-3+ DCs | (60) |
| PCM | IHC | 82 primary tumor samples | Human | LAMP-3 | LAMP-3+ DCs aggregated around activated T cells & together provided a strong prognosis for survival | LAMP-3+ DCs | (59) |
| HNSCC | RNA seq & cohorts with multivariate analysis | TCGA-HNSCC database & human tumors | Human | LAMP-3 | LAMP-3+ DCs are found within TLSs, and these are correlated with better prognosis | LAMP-3+ DCs | (58) |
| Mass cytometry & bulk RNA seq | Primary & metastatic tumors | Human | Cd274, Pdcd1lg2, Cd40, Cd80, Cd86, Cd200, Il4i1, Il4r, Il12b, Ccr7 | mregDCs enrich Tregs by expressing CCR7 & CD127. They also produce IL-23, which increases IL-17 production by Th17 & exhausted CD8+ T cells, which has a favorable prognosis | mregDCs | (32) | |
| LLC & Colon26 | Flow cytometry | Tumor samples from minP1, anti-PD-L1, minP1+anti-PD-L1 treated & untreated | Mice | CCR7+, CD11b+, CD11c+, CD14-, Ly6c-, MHC-II+, from lineage-negative cell population: CD3-, CD19-, Ly6G | All treatments increased the number of intratumoral mregDCs, while being correlated with an expansion of intratumoral progenitor CD8+ T cells while decreasing terminally exhausted CD8+ T cells. Enhancing the prognosis & favoring survival | mregDCs | (69) |
| scRNA seq | Tumor samples from minP1, anti-PD-L1, minP1+anti-PD-L1 treated & untreated | Mice | Fscn1, IL12b, Ccl22 | minP1 upregulated the presentation of MHC-II antigens on mregDCs. The treatments exerted better prognosis & survival | mregDCs | (69) | |
| TNBC | scRNA seq | Tumors from retrospective clinical trials | Human | Ccl19, Ccr7, Lamp3, Fscn1 | CCL19+ DCs indicated better response to anti-PD-1 and were also expanded in responsive tumors. Experienced CD8+ T cells were predictive for response to anti-PD-1, and these cells were increased in CCL19+ DC-enriched tumors | CCL19+ DCs | (70) |
| LLC1 | scRNA seq | Tumors from two clinical trials | Human | Ccr7, Il12b, Ccl22 | PGE antagonism decreased tumor growth, by reducing the production of CCL17 & CCL22 by mregDCs, which lowers the tumor-infiltrating Tregs, which benefits inflammation | mregDCs | (67) |
| HCC | scRNA seq & staining | Tumor lesions from responders & non-responders of anti-PD-1 | Human | Cd274, Ccr7, Ccl22, Birc3, Ido1, Il4i1, Lamp3 | Cellular triads consisting of mregDCs, CXCL13+, CD4+ Th & progenitor CD8+ T cells were found in responding tumors, and deemed critical for the differentiation of progenitor CD8+ T cells into effective antitumor CD8+ T cells in response to PD-1 blockade | mregDCs | (46) |
| NSCLC | scRNA seq & CITE-seq | Naïve & tumor-bearing lungs | Human & mice | Cd274, Pdcd1lg2, Cd200, Cd40, Ccr7, Il12b, Cd80, Cd86, Cd83, Relb, Fas, Socs1, Socs2, Aldh1a2 | IL-4 blocking resulted in increased production of IL-12 by mregDCs, which enhanced the T cell activation, and expansion of IFNγ+, CD8+ effector T cells resulting in reduced tumor growth | mregDCs | (22) |
IHC: immunohistochemistry; ESCC: esophageal squamous cell carcinoma; PCM: primary cutaneous melanoma; HNSCC: head and neck squamous cell carcinoma; LLC: Lewis lung carcinoma; HCC: Hepatocellular carcinoma; NSLC: Non-small cell lung cancer; TCGA: The Cancer Genome Atlas; TNBC: triple-negative breast cancer.